Subcutaneous semaglutide demonstrated cardiovascular benefit in T2DM back in 2016 (SUSTAIN-6) with 26% MACE reduction. Oral semaglutide demonstrates cardiovascular risk reduction in T2DM and high CV risk in the newly published SOUL trial with 14% MACE reduction with albeit a

🚨 New in CGH 🚨 Waist-to-height ratio (WHtR) >>> BMI/waist in predicting: 🔑 Severe hepatic steatosis (AUROC 0.79) 🔑Advanced fibrosis (AUROC 0.78) 🔑 Especially effective in Hispanics Elliot Tapper Thiago Pitt Medicine Chiefs Pitt General Internal Medicine BIDMC_GI cghjournal.org/article/S1542-…

How do we learn? Life—and medicine—is built on automatic moves, as we're usually good at predicting what comes next. But consciousness arises from prediction errors. And only through consciousness can learning happen!

Skeletal muscle 💪 should be viewed as a vital metabolic organ 🧬. Preserving lean mass during weight loss ⚖️ is essential for physical performance 🏃‍♂️ and long-term metabolic health ❤️‍🩹. The risks of muscle loss, from impaired gly-caemic control 🩸 to loss of independence 🧑‍🦽,